Continuous Glucose Monitoring Devices Market to Reach US$10.72 Billion by 2033 | CAGR 8.1% | North America Leads with 42% Share | Key Players: Abbott, Dexcom, Medtronic

Market Overview

The global continuous glucose monitoring (CGM) devices market was valued at US$ 5.24 billion in 2023, growing to US$ 5.61 billion in 2024, and is expected to reach US$ 10.72 billion by 2033, registering a CAGR of 8.1% during 2025-2033. The market growth is primarily driven by the rising prevalence of diabetes worldwide, which has heightened the demand for effective blood glucose management solutions. Clinical evidence increasingly supports the benefits of real-time glucose monitoring in reducing diabetes-related complications, driving greater adoption among healthcare providers and patients alike.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/continuous-glucose-monitoring-devices-market?Juli

Technological advancements are also shaping market dynamics. Improvements in sensor accuracy, extended wear duration, and integration with insulin delivery systems have enhanced patient adherence and clinician confidence. Additionally, the trend toward digital health platforms enables CGM data to sync with mobile apps, remote monitoring tools, and telemedicine services, strengthening patient engagement and enabling proactive disease management.

Key trends include:

Digital Health Integration: Seamless connectivity with apps, smart insulin pens, and pumps improves adherence and real-time decision-making. Sensor Innovations: Longer-lasting, more accurate, and minimally invasive sensors enhance patient convenience and clinical reliability. Personalized Healthcare & Preventive Wellness: CGMs are being adopted beyond diabetes management, for fitness, sports performance, and general health monitoring.

Opportunities are particularly strong in low- and middle-income countries, where rising diabetes prevalence coincides with low device penetration due to cost and awareness barriers. Manufacturers can leverage AI-powered analytics, coaching platforms, and remote monitoring programs to enhance device value and establish new revenue streams.

Recent Developments:

✅ January 2026 - Global: A leading medical technology company launched a next‐generation CGM system featuring enhanced sensor accuracy, extended wear life up to 14 days, and improved integration with mobile health platforms for real‐time glucose trend visualization.

✅ November 2025 - North America: A major CGM manufacturer announced FDA clearance for a wearable, patch‐based CGM device with automated data sharing, enabling seamless remote monitoring by caregivers and healthcare providers.

✅ In September 2024, Senseonics Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved the next-generation Eversense 365 CGM system. This innovative system is designed for adults aged 18 and older with Type 1 or Type 2 diabetes. Eversense 365 is the world's first CGM system that lasts for a full year, marking a major advancement in diabetes management and technology.

✅ In August 2024, Dexcom introduced the first over-the-counter (OTC) continuous glucose monitor (CGM) in the United States, called the Stelo Glucose Biosensor System. This device is significant because it is the first CGM cleared by the U.S. Food and Drug Administration (FDA) that does not require a prescription, making it more accessible to adults aged 18 and older who do not use insulin such as those with type 2 diabetes managed by oral medications or people without diabetes who want to monitor how diet and exercise affect their blood sugar

Mergers & Acquisitions:

✅ February 2026 - North America: A leading diabetes technology company acquired a CGM data analytics startup, strengthening its portfolio with advanced predictive algorithms and real‐time glucose trend analysis capabilities integrated across its device suite.

✅ October 2025 - Europe: A major global medical device manufacturer completed the takeover of a wearable biosensor firm specializing in flexible, minimally invasive glucose sensing materials, enhancing its long‐wear CGM offerings.

✅ July 2025 - Asia‐Pacific: A regional healthcare technology provider merged with a CGM sensor manufacturing company to expand production capacity and localize supply chains, reducing reliance on imports and improving device affordability in emerging markets.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=continuous-glucose-monitoring-devices-market?Juli

Key Players:

Abbott, Dexcom, Inc., Medtronic Pvt. Ltd., Ascensia Diabetes Care Holdings AG., F. Hoffmann-La Roche Ltd, iHealth Labs Inc., Ypsomed AG, Medtrum Technologies Inc., Menarini Diagnostics s.r.l Nemaura, Senseonics, Glucovation, Inc., Afon Technology, and Signos Inc.

Market Segmentation:

By Component: Sensors dominate the market with around 55% share, as they are the core technology enabling real-time glucose detection. Transmitters account for approximately 25%, facilitating wireless data transfer from the sensor to devices or apps. Receivers, such as dedicated displays or mobile apps, hold about 20% of the market, allowing patients and clinicians to monitor glucose readings efficiently.

By Connectivity: Bluetooth connectivity leads with around 62% share, driven by its widespread compatibility with smartphones, smartwatches, and insulin pumps. Wi-Fi connectivity contributes about 38%, mainly used in clinical settings and homecare for remote patient monitoring and cloud-based data integration.

By Application: Type 1 diabetes remains the largest segment with a 45% share, due to the critical need for continuous monitoring in insulin-dependent patients. Type 2 diabetes accounts for around 35%, supported by increasing awareness and adoption of CGM devices among non-insulin-dependent patients. Gestational diabetes contributes approximately 12%, while prediabetes monitoring represents 8%, reflecting early adoption trends in preventive healthcare.

By End-User: Hospitals and clinics are the primary end-users, representing roughly 40% of the market, leveraging CGM devices for both inpatient and outpatient care. Homecare settings follow with around 35%, as patients increasingly adopt CGM devices for self-monitoring and integration with telehealth. Diagnostic centers hold about 15%, while specialized diabetes care centers account for the remaining 10%, focusing on patient education and advanced monitoring programs.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/continuous-glucose-monitoring-devices-market?Juli
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Regional Insights:

North America: North America is the largest regional market, holding approximately 42% of the global CGM revenue. The strong presence of leading manufacturers such as Abbott, Dexcom, and Medtronic, coupled with advanced healthcare infrastructure and high adoption of digital health technologies, drives this dominance. Rising awareness of diabetes management, widespread reimbursement policies, and robust telehealth integration further bolster market growth.

Europe: Europe accounts for around 25% of the market share, supported by increasing prevalence of diabetes, strong regulatory frameworks for medical devices, and high adoption of CGM in both hospitals and homecare. Countries like Germany, the UK, and France are early adopters of CGM technology, while initiatives promoting personalized healthcare and preventive monitoring contribute to steady market expansion.

Asia-Pacific: Asia-Pacific is the fastest-growing regional market, contributing about 22% of the global share. Rapid urbanization, rising diabetes prevalence, expanding healthcare access, and growing disposable incomes in countries such as China, India, Japan, and South Korea are driving adoption. The increasing focus on homecare monitoring and telemedicine is creating significant growth opportunities for CGM devices in this region.

Market Dynamics:

Drivers - Technological Advancements
Technological innovations are a major growth driver for the global CGM market. Advances in sensor technology have greatly improved the accuracy, reliability, and lifespan of CGM devices. Modern sensors provide real-time glucose readings with minimal lag and extended wear times, sometimes lasting several months, which reduces the frequency of replacements and enhances user convenience.

Integration with wireless connectivity, such as Bluetooth and NFC, enables CGM systems to automatically sync data with smartphones, smartwatches, and cloud-based platforms. This allows both users and healthcare providers to access glucose data remotely, facilitating telemedicine, remote monitoring, and timely clinical interventions especially important in rural or underserved areas.

The incorporation of artificial intelligence (AI) and advanced analytics into CGM apps further enhances patient care. AI can analyze glucose trends, predict potential highs and lows, and provide personalized guidance on diet, exercise, and medication. For example, in June 2025, Tracky a healthtech brand by DrStore Healthcare Services launched India's first Bluetooth-connected CGM, representing a major step forward in diabetes care and preventive health management. These technological innovations are significantly boosting market demand and adoption globally.

Restraints:
The high cost of CGM devices remains a key market restraint, limiting adoption, particularly in low- and middle-income countries (LMICs). CGM systems require purchasing not only the initial device but also recurring consumables, such as sensors and transmitters, which need frequent replacement.

For instance, monthly costs for CGM use range from US$100 to US$300, and annual expenses can be considerably higher. In LMICs, where most patients pay out-of-pocket due to limited insurance coverage, these costs often make CGMs inaccessible. This financial barrier not only affects individual users but also has broader public health implications, as people unable to afford CGMs may experience poorer glycemic control, increased complications, and higher long-term healthcare costs, limiting overall market growth.

Opportunities - Expanding Use in Non-Insulin and Pre-Diabetic Populations
A significant growth opportunity lies in the adoption of CGM devices among non-insulin users and pre-diabetic populations. While CGMs were initially used primarily by people with insulin-dependent diabetes, recent trends show increasing usage among type 2 diabetes patients on oral medications, pre-diabetic individuals, and health-conscious consumers.

CGMs provide real-time, detailed glucose insights that can reveal early abnormalities such as postprandial hyperglycemia or the dawn phenomenon, enabling timely lifestyle interventions. For pre-diabetic populations, early detection allows for dietary adjustments, increased physical activity, and other preventive measures, helping delay or prevent progression to type 2 diabetes. This expansion beyond traditional diabetes care is opening new revenue streams and broadening the market potential for CGM devices worldwide.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring
☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.